Linus Health to Present New Research Findings at Leading Alzheimer's and Parkinson's Conference

AD/PD™ 2025 to feature presentations on Linus Health's digital cognitive health assessments, plus attendees can learn more about company's recent life-sciences market growth

BOSTON, March 25, 2025 /PRNewswire/ -- Linus Health, which is revolutionizing brain health with science-driven digital solutions, will present findings from two new research studies as well as updates on the company's growth in the life sciences market at AD/PD™, a leading international conference for Alzheimer's and Parkinson's diseases.

AD/PD, now in its 40th year and taking place April 1-5 in Vienna, Austria, uniquely combines distinct neurodegenerative diseases in one setting and examines their similarities and differences, with a strong focus on mechanisms of disease, prevention, and therapy. In 2024, the conference attracted more than 4,700 healthcare, life sciences, and scientific professionals from over 70 countries.

Linus Health will deliver poster presentations at AD/PD from two clinical studies evaluating the accuracy, efficacy, and value of its digital health solutions that detect the early indicators of cognitive and motor impairment. The presentations, which will be available online as e-posters, are:

"DCTclock Detects Cognitive and Motor Impairment in Parkinson's Disease and Quantifies Drawing Tremor"

Presented by Ali Jannati, MD, PhD, Linus Health's director of Cognitive Science, this study found that the Linus Health DCTclock™ detects cognitive impairment in Parkinson's disease (PD) and differentiates between varying levels of cognitive function among patients with PD. Dr. Jannati and the team concluded that the solution's Oscillatory Motion (OM) metric accurately quantifies drawing tremors and aligns closely with clinician ratings. These results establish DCTclock and its metrics as novel and sensitive endpoints for assessing cognitive and motor impairment, including tremor detection, in patients with Parkinson's disease.

"Neuropsychological Validation of a Brief Protocol for Digital Assessment of Cognition"

Also authored and presented by Dr. Jannati and the team, this study validates that Linus Health's 7-minute Digital Assessment of Cognition (DAC), which utilizes patient speech responses, achieves high accuracy in classifying cognitive status, aligning closely with a traditional 3-hour neuropsychological evaluation. The authors conclude that the DAC offers a rapid, scalable solution for remote or in-person cognitive evaluation, with the potential to substantially increase the efficiency and throughput of specialists' workflow.

"We are excited to present two of the recent validations of our evidence-based digital cognitive health platform at a leading global conference on the most innovative science and therapy surrounding Alzheimer's and Parkinson's disease," Dr. Jannati said. "The findings highlight the value of our solutions for clinicians, researchers, and patients. As a highly sought-after conference for life science professionals, we are also eager to share with attendees some recent developments and expansion in that market."

Life Sciences Growth
At Linus Health's booth (#79), AD/PD attendees can learn more about these and other recent study findings and how life sciences organizations are using the company's solutions to support clinical trials and research. Adoption is being fueled by Linus Health's extensive library of 145 published peer-reviewed studies and track record of fostering clinical trial operational efficiency. These biopharma companies also recognize that meaningful advances in new neurodegenerative and mental health therapies will not be feasible without healthcare provider collaboration.

Linus Health's 2024 acquisition of Aural Analytics expanded its life sciences footprint. Linus Health now offers Speech Vitals, an established AI-driven speech analytics solution alongside its broad array of over 30 assessments within the Linus Health platform.

Today, many of the world's largest pharmaceutical and life sciences companies are leveraging Linus Health's solutions to support brain health research, including clinical trials for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), as well as mental and behavioral health studies for depression, schizophrenia, and other conditions.

Linus Health's advanced digital solutions accelerate clinical trial recruitment and enhance the robustness of study outcome measures. Traditional recruitment is often slow, expensive, and marked by high screening failure rates. Linus Health's remote and in-clinic assessments help pre-screen individuals efficiently, enabling clinical sites to identify and enroll suitable participants with greater speed and confidence. Thanks to the sensitivity of AI-based technology, researchers also rely on Linus Health to strengthen outcome measurements and accurately assess the impact of novel treatments. Beyond trials, Linus Health supports post-market studies in real-world clinical settings to monitor the safety, efficacy, and long-term benefits of new therapies.

"Linus Health is working with more pharma and life sciences companies than ever before because we help solve their most pressing challenge: increasing clinical trial efficiency and success while maintaining scientific rigor and capturing meaningful results," said Linus Health CEO and co-founder David Bates, PhD. "We look forward to sharing with AD/PD attendees the many examples of how we help optimize research into life-changing therapies."

About Linus Health
Linus Health is a Boston-based digital health company focused on transforming brain health for people across the world. By advancing how we detect and address cognitive and brain disorders – leveraging cutting-edge neuroscience, clinical expertise, and artificial intelligence – our goal is to enable a future where people can live longer, happier, and healthier lives with better brain health. Linus Health's digital cognitive assessment platform delivers a proven, practical means of enabling early detection; empowers providers with actionable clinical insights; and supports individuals with personalized action plans. We are proud to partner with leading healthcare delivery organizations, research institutions, and life sciences companies to accelerate more proactive intervention and personalized care in brain health. To learn more about our practical solutions for proactive brain health®, visit www.linushealth.com or follow us on LinkedIn.

Media Contact
Tara Stultz (Amendola for Linus Health)
440-225-9595
[email protected]

SOURCE Linus Health